Suda Pharmaceuticals - A potentially transformational acquisition
SUDA recently announced that it will be licensing an invariant natural killer T (iNKT) cell therapy platform from Imperial College London that can...
1.1k Views
Suda Pharmaceuticals - A TGA approval and a capital raise
SUDA has had a busy couple of months, announcing approval for ZolpiMist in Australia by the Therapeutics Goods Administration (TGA) in July, as...
88 Views
Suda Pharmaceuticals - Improving delivery of existing drug products
SUDA Pharmaceuticals has focused on reformulating established drugs into oro-mucosal spray formulations for better bioavailability. Its lead...
89 Views
No more insights